ID   SJ-HGGX2c
AC   CVCL_C1NJ
SY   SJHGG009024_C2
DR   cancercelllines; CVCL_C1NJ
DR   Wikidata; Q114313024
RX   PubMed=34215733;
WW   https://pbtp.stjude.cloud/sample-details/29958/baker/SJHGG009024/SJ-HGGX2/Cell%20Line
CC   Characteristics: Derived from a patient-derived xenograft.
CC   Doubling time: 8.2 days (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Asn659Lys (c.1977C>G); ClinVar=VCV000375902; Zygosity=Homozygous (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Trp (c.405C>G); ClinVar=VCV000376561; Zygosity=Homozygous (PubMed=34215733).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Brain, cerebellum; UBERON=UBERON_0002037.
ST   Source(s): PubMed=34215733
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 9,12
ST   D18S51: 16
ST   D21S11: 30
ST   D3S1358: 15,16
ST   D5S818: 10,11
ST   D7S820: 10
ST   D8S1179: 15
ST   FGA: 24,25
ST   Penta D: 2.2,5
ST   Penta E: 8
ST   TH01: 6,9.3
ST   TPOX: 10,11
ST   vWA: 15,16
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   4-5Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=34215733; DOI=10.1038/s41467-021-24168-8; PMCID=PMC8253809;
RA   He C., Xu K., Zhu X.-Y., Dunphy P.S., Gudenas B., Lin W.-W., Twarog N.,
RA   Hover L.D., Kwon C.-H., Kasper L.H., Zhang J.-Y., Li X.-Y., Dalton J.,
RA   Jonchere B., Mercer K.S., Currier D.G., Caufield W., Wang Y.-Z., Xie J.,
RA   Broniscer A., Wetmore C., Upadhyaya S.A., Qaddoumi I., Klimo P.,
RA   Boop F., Gajjar A., Zhang J.-H., Orr B.A., Robinson G.W., Monje M.,
RA   Freeman B.B. 3rd, Roussel M.F., Northcott P.A., Chen T.-S., Rankovic Z.,
RA   Wu G., Chiang J.C.-H., Tinkle C.L., Shelat A.A., Baker S.J.;
RT   "Patient-derived models recapitulate heterogeneity of molecular
RT   signatures and drug response in pediatric high-grade glioma.";
RL   Nat. Commun. 12:4089.1-4089.17(2021).
//